Bayesian designs and the control of frequentist characteristics: A practical solution

作者: Steffen Ventz , Lorenzo Trippa

DOI: 10.1111/BIOM.12226

关键词:

摘要: Frequentist concepts, such as the control of type I error or false discovery rate, are well established in medical literature and often required by regulators. Most Bayesian designs defined without explicit considerations frequentist characteristics. Once design is structured, statisticians use simulations adjust tuning parameters to comply with a set targeted operating These adjustments affect prior information utility functions. Here we consider decision theoretic approach for experimental requisites. We define optimal under constraints regulator. Our combines interpretable functions criteria, selects an that satisfies illustrate using group-sequential multi-arm Phase II trial bridging trial.

参考文章(34)
John W. Pratt, Bayesian Interpretation of Standard Inference Statements Journal of the Royal Statistical Society: Series B (Methodological). ,vol. 27, pp. 169- 192 ,(1965) , 10.1111/J.2517-6161.1965.TB01486.X
Keith R. Abrams, David J. Spiegelhalter, Jonathan P. Myles, Bayesian Approaches to Clinical Trials and Health-Care Evaluation ,(2004)
P. Armitage, C. K. McPherson, B. C. Rowe, Repeated Significance Tests on Accumulating Data Journal of the Royal Statistical Society: Series A (General). ,vol. 132, pp. 235- 244 ,(1969) , 10.2307/2343787
Michael A. Proschan, K. K. Gordan Lan, Janet Turk Wittes, Statistical Monitoring of Clinical Trials: A Unified Approach ,(2006)
Ming-Hui Chen, Joseph G. Ibrahim, The relationship between the power prior and hierarchical models Bayesian Analysis. ,vol. 1, pp. 551- 574 ,(2006) , 10.1214/06-BA118
A.B. Sandler, J. Nemunaitis, C. Denham, J. von Pawel, Y. Cormier, U. Gatzemeier, K. Mattson, Ch. Manegold, M.C. Palmer, A. Gregor, B. Nguyen, C. Niyikiza, L.H. Einhorn, Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 18, pp. 122- 122 ,(2000) , 10.1200/JCO.2000.18.1.122
Boris Freidlin, Edward L. Korn, Robert Gray, Alison Martin, Multi-Arm Clinical Trials of New Agents: Some Design Considerations Clinical Cancer Research. ,vol. 14, pp. 4368- 4371 ,(2008) , 10.1158/1078-0432.CCR-08-0325
Roger J. Lewis, Donald A. Berry, Group sequential clinical trials: a classical evaluation of Bayesian decision-theoretic designs Journal of the American Statistical Association. ,vol. 89, pp. 1528- 1534 ,(1994) , 10.1080/01621459.1994.10476893
David J. Spiegelhalter, Laurence S. Freedman, Mahesh K. B. Parmar, Bayesian Approaches to Randomized Trials Journal of The Royal Statistical Society Series A-statistics in Society. ,vol. 157, pp. 357- 387 ,(1994) , 10.2307/2983527